NasdaqGS - Nasdaq Real Time Price USD

Sarepta Therapeutics, Inc. (SRPT)

130.04 -2.26 (-1.71%)
As of 1:16 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,403,300.00
1,243,336.00
933,013.00
701,887.00
540,099.00
Cost of Revenue
165,885.00
150,343.00
139,989.00
97,049.00
63,382.00
Gross Profit
1,237,415.00
1,092,993.00
793,024.00
604,838.00
476,717.00
Operating Expense
1,332,246.00
1,360,817.00
1,329,225.00
1,054,548.00
1,040,880.00
Operating Income
-94,831.00
-267,824.00
-536,201.00
-449,710.00
-564,163.00
Net Non Operating Interest Income Expense
66,698.00
63,959.00
-25,525.00
-63,014.00
-56,977.00
Other Income Expense
62,193.00
-316,233.00
-128,237.00
93,776.00
68,075.00
Pretax Income
34,060.00
-520,098.00
-689,963.00
-418,948.00
-553,065.00
Tax Provision
17,163.00
15,879.00
13,525.00
-168.00
1,063.00
Net Income Common Stockholders
16,897.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Diluted NI Available to Com Stockholders
17,326.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Basic EPS
0.44
-5.80
-8.03
-5.15
-7.11
Diluted EPS
0.43
-5.80
-8.03
-5.15
-7.11
Basic Average Shares
93,849.25
92,398.00
87,559.00
81,262.00
77,956.00
Diluted Average Shares
95,130.00
92,398.00
87,559.00
81,262.00
77,956.00
Total Operating Income as Reported
-94,831.00
-267,824.00
-536,201.00
-459,710.00
-564,163.00
Total Expenses
1,498,131.00
1,511,160.00
1,469,214.00
1,151,597.00
1,104,262.00
Net Income from Continuing & Discontinued Operation
16,897.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Normalized Income
41,869.60
-205,085.50
-607,648.36
-411,492.00
-521,278.00
Interest Income
86,551.00
85,969.00
27,723.00
511.00
2,970.00
Interest Expense
19,853.00
22,010.00
53,248.00
63,525.00
59,947.00
Net Interest Income
66,698.00
63,959.00
-25,525.00
-63,014.00
-56,977.00
EBIT
53,913.00
-498,088.00
-636,715.00
-355,423.00
-493,118.00
EBITDA
95,749.00
-453,691.00
-594,851.00
-317,406.00
-466,207.00
Reconciled Cost of Revenue
126,031.00
107,505.00
98,839.00
59,738.00
37,133.00
Reconciled Depreciation
41,836.00
44,397.00
41,864.00
38,017.00
26,911.00
Net Income from Continuing Operation Net Minority Interest
16,897.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Total Unusual Items Excluding Goodwill
-41,621.00
-418,850.00
-121,316.00
-7,288.00
-45,000.00
Total Unusual Items
-41,621.00
-418,850.00
-121,316.00
-7,288.00
-45,000.00
Normalized EBITDA
137,370.00
-34,841.00
-473,535.00
-310,118.00
-421,207.00
Tax Rate for Calcs
0.00
0.00
0.00
--
0.00
Tax Effect of Unusual Items
-16,648.40
-87,958.50
-25,476.36
--
-12,150.00
12/31/2020 - 6/4/1997

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MDGL Madrigal Pharmaceuticals, Inc.
204.71
-1.07%
 
APLS Apellis Pharmaceuticals, Inc.
41.78
-1.75%
 
JANX Janux Therapeutics, Inc.
49.49
-4.72%
 
CTMX CytomX Therapeutics, Inc.
1.9299
-5.40%
 
AXSM Axsome Therapeutics, Inc.
73.40
-0.38%
 
VKTX Viking Therapeutics, Inc.
74.18
-7.50%
 
BLUE bluebird bio, Inc.
1.0500
-6.25%
 
KRYS Krystal Biotech, Inc.
156.26
-1.56%
 
BMRN BioMarin Pharmaceutical Inc.
80.78
-1.15%
 
ALNY Alnylam Pharmaceuticals, Inc.
149.03
-1.54%